Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H15N2O2.Cl |
Molecular Weight | 182.649 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[N+](C)(C)CCOC(N)=O
InChI
InChIKey=AIXAANGOTKPUOY-UHFFFAOYSA-N
InChI=1S/C6H14N2O2.ClH/c1-8(2,3)4-5-10-6(7)9;/h4-5H2,1-3H3,(H-,7,9);1H
Molecular Formula | C6H15N2O2 |
Molecular Weight | 147.1955 |
Charge | 1 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 |
6.0 mM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | MIOSTAT Approved UseIntraocular use for obtaining miosis during surgery. In addition, MIOSTAT (carbachol intraocular solution, USP) reduces the intensity of intraocular pressure elevation in the first 24 hours after cataract surgery. Launch Date1972 |
PubMed
Title | Date | PubMed |
---|---|---|
Spasmolytic constituents of Cedrus deodara (Roxb.) Loud: pharmacological evaluation of himachalol. | 1975 Feb |
|
Evidence that a nigral gabaergic--cholinergic balance controls posture. | 1979 Jan 1 |
|
Neuropharmacology of the parasitic trematode, Schistosoma mansoni. | 1983 Jan |
|
Drug-induced modulation of locomotor hyperactivity induced by picrotoxin in nucleus accumbens. | 1984 Oct |
|
Neuropeptide Y and calcitonin gene-related peptide: effects on glucagon and insulin secretion in the mouse. | 1987 |
|
Spinal cholinergic neurons and the expression of morphine withdrawal symptoms in the rat. | 1987 Mar |
|
Novel 'soft' anticholinergic agents. | 1988 Feb |
|
Anatomical analysis of frontal cortex sites at which carbachol induces motor seizures in the rat. | 1988 May |
|
Plasma catecholamines and alpha 1-adrenoceptor function in hemodialysis-associated hypotension. | 1990 |
|
Dopaminergic drugs influence the intensity of catalepsy induced by microinjections of carbachol into the reticular formation. | 1990 Nov 13 |
|
Studies on the development of tolerance and potential spinal neurotoxicity after chronic intrathecal carbachol-antinociception in the rat. | 1991 Feb |
|
Positive and negative feedback regulation of choline acetyltransferase mRNA levels in Drosophila: a study using temperature-sensitive mutants and embryo cell cultures. | 1992 Apr |
|
Vagus nerve modulates secretin binding sites in the rat forestomach. | 1999 Apr |
|
Myoclonic and tonic seizures elicited by microinjection of cholinergic drugs into the inferior colliculus. | 1999 Sep-Oct |
|
Carbachol blocks beta-amyloid fragment 31-35-induced apoptosis in cultured cortical neurons. | 2000 Apr |
|
Low-affinity M(2) receptor binding state mediates mouse atrial bradycardia: comparative effects of carbamylcholine and the M(1) receptor agonists sabcomeline and xanomeline. | 2001 Mar |
|
The role of endogenous human Trp4 in regulating carbachol-induced calcium oscillations in HEK-293 cells. | 2002 Apr 19 |
|
Design, pharmacokinetic, and pharmacodynamic evaluation of soft anticholinergics based on tropyl alpha-phenylcyclopentylacetate. | 2002 Feb |
|
Impaired parasympathetic heart rate control in mice with a reduction of functional G protein betagamma-subunits. | 2002 Feb |
|
Pharmacological characterization of recombinant bovine alpha3beta4 neuronal nicotinic receptors stably expressed in HEK 293 cells. | 2003 Jun 12 |
|
Design, pharmacokinetic, and pharmacodynamic evaluation of a new class of soft anticholinergics. | 2003 Oct |
|
Crucial role of histamine for regulation of gastric acid secretion ascertained by histidine decarboxylase-knockout mice. | 2003 Oct |
|
Cyclic AMP/protein kinase a signal attenuates Ca(2+)-induced fibroblast growth factor-1 synthesis in rat cortical neurons. | 2004 Aug 15 |
|
Post-seizures amygdaloallocortical microvascular lesion leading to atrophy and memory impairment. | 2005 Aug |
|
Pharmacokinetic and pharmacodynamic evaluations of the zwitterionic metabolite of a new series of N-substituted soft anticholinergics. | 2005 Dec |
|
[Effects of carbachol on apoptosis of peripheral white blood cells and expression of cytokines in rats suffering from gut ischemia/reperfusion injury]. | 2005 Feb |
|
Neuronal nitric oxide synthase activity in rat urinary bladder detrusor: participation in M3 and M4 muscarinic receptor function. | 2005 Jul |
|
Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. | 2005 Jun |
|
Actin and non-muscle myosin II facilitate apical exocytosis of tear proteins in rabbit lacrimal acinar epithelial cells. | 2005 Oct 15 |
|
Case report: acute unintentional carbachol intoxication. | 2006 |
|
Muscarinic acetylcholine receptors mediate oligodendrocyte progenitor survival through Src-like tyrosine kinases and PI3K/Akt pathways. | 2006 Apr |
|
Novelty exploration elicits a reversal of acute stress-induced modulation of hippocampal synaptic plasticity in the rat. | 2006 Dec 1 |
|
Muscarinic cholinoceptor activation modulates DNA synthesis and CD40 expression in fibroblast cells. | 2006 Jul |
|
Myosin light chain kinase-independent inhibition by ML-9 of murine TRPC6 channels expressed in HEK293 cells. | 2007 Sep |
|
Structural and functional effects of developmental exposure to ethanol on the zebrafish heart. | 2010 Jun |
|
The validation of an in vitro colonic motility assay as a biomarker for gastrointestinal adverse drug reactions. | 2010 Jun 15 |
|
TRPC5 channel sensitivities to antioxidants and hydroxylated stilbenes. | 2011 Feb 18 |
Patents
Sample Use Guides
MIOSTAT (CARBACHOL INTRAOCULAR SOLUTION, USP) 0.01%
Aseptically remove the sterile vial from the blister package by peeling the backing paper and dropping the vial onto a sterile tray. Withdraw the contents into a dry sterile syringe, and replace the needle with an atraumatic cannula prior to intraocular instillation. No more than one-half milliliter should be gently instilled into the anterior chamber for the production of satisfactory miosis. It may be instilled before or after securing sutures. Miosis is usually maximal within two to five minutes after application.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27118568
In the dose-course studies, carbachol showed significant increase in phosphorylation of MYPT1 at Thr696 (p-MYPT1) from concentrations of 15-100 μM based on Western blot results (p < 0.05, ANOVA test). In the time-course studies, treatment of cells with 15 μM of carbachol significantly enhanced the expression of p-MYPT1 from 3 to 15 h (p < 0.05, ANOVA test) and induced the expression of Rho A from 10 to 120 min (p < 0.05, ANOVA test).
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:49:17 GMT 2025
by
admin
on
Mon Mar 31 17:49:17 GMT 2025
|
Record UNII |
8Y164V895Y
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29705
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-ATC |
S01EB02
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-ATC |
N07AB01
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
NDF-RT |
N0000175884
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-VATC |
QS01EB02
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
||
|
WHO-VATC |
QA03AB92
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5831
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
C47430
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
DB00411
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
32865
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
488
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
SUB06087MIG
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
298
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
m3051
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
D002217
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL965
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
DTXSID9022730
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
3385
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
51-83-2
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
6373
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
1092009
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
1999
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
383
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
8Y164V895Y
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
Carbachol
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
100000081628
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
200-127-3
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY | |||
|
Carbachol
Created by
admin on Mon Mar 31 17:49:17 GMT 2025 , Edited by admin on Mon Mar 31 17:49:17 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Duration of Action | PHARMACOKINETIC |
|
INTRAOCULAR ADMINISTRATION PHARMACOKINETIC |
|
||